Abstract

NeoGenomics will report quarterly results on April 28, 2026 Post Market; this preview distills consensus expectations, key financial metrics from the prior quarter, and what investors should watch in the company’s revenue, profitability, and execution catalysts this quarter.

Market Forecast

Consensus points to revenue of 184.53 million US dollars for the current quarter, implying 7.94% year-over-year growth, an adjusted EPS estimate of 0.007 US dollars with a 161.58% year-over-year increase off a small base, and EBIT of -19.97 million US dollars reflecting a 23.07% year-over-year improvement; margin forecasts were not provided. The company did not issue quarterly margin guidance in its last report, though it guided 2026 full-year revenue to a range of 793.00–801.00 million US dollars, framing an improving trajectory through the year. Main business momentum is expected to be anchored by testing demand and pricing discipline, with payer mix remaining a key profitability lever as the company scales high-complexity oncology assays. The most promising pipeline addition is the RaDaR ST molecular residual disease assay, launched in February 2026 with Medicare coverage in initial indications; its near-term revenue contribution is expected to ramp from a small base as clinical adoption builds year over year.

Last Quarter Review

NeoGenomics delivered revenue of 190.17 million US dollars, a gross profit margin of 43.83%, GAAP net profit attributable to shareholders of -9.88 million US dollars with a net profit margin of -5.20%, and adjusted EPS of 0.06 US dollars, with revenue up 10.56% year over year and adjusted EPS up 50% year over year. A notable financial highlight was the outperformance versus Street expectations, with revenue and adjusted EPS both coming in ahead of consensus in the prior report. By channel, last quarter’s payer mix was led by client-direct billing at 518.84 million US dollars, followed by commercial insurance at 117.51 million US dollars, Medicare and other government payors at 90.87 million US dollars, and self-pay at 0.11 million US dollars; the overall top line increased 10.56% year over year.

Current Quarter Outlook

Core Testing Revenue and Payer Mix

The market expects the core testing business to deliver 184.53 million US dollars in revenue this quarter, up 7.94% year over year, pointing to steady demand trends following a strong holiday-quarter exit. Given the prior quarter’s 43.83% gross margin, investors will watch whether mix shift toward higher-complexity oncology assays and operating leverage can offset seasonal volume normalization and help maintain or gradually expand gross margin. Payer dynamics remain central: the prior quarter’s channel mix was led by client-direct billing in absolute dollars, and continued traction with commercial insurers and stable government reimbursement underpin revenue quality and collection cycles. On the bottom line, consensus implies adjusted EPS of 0.007 US dollars and EBIT of -19.97 million US dollars, suggesting ongoing investment while margins continue to work back toward breakeven. Execution on test turn-around time, report quality, and menu breadth can influence both volume and price realization, which are key to bridging the gap from negative EBIT to sustainable profitability. With no company-issued quarterly margin guidance, investors will infer trajectory from volume indicators, reimbursement updates, and expense discipline communicated on April 28, 2026.

RaDaR ST and Advanced Oncology Assays

The RaDaR ST molecular residual disease (MRD) test, launched in February 2026 with Medicare coverage in selected initial indications and two additional indications reimbursable, introduces a new revenue stream that could compound over the year as providers integrate it into care pathways. Early quarters typically show small revenue contributions as ordering patterns form, physician education scales, and medical policy coverage broadens; the slope of adoption, not the absolute contribution this quarter, is the critical signal for medium-term growth. MRD testing also crosses over into the company’s relationships with biopharma customers, as minimal residual disease measurement can be embedded in trial design and companion diagnostic development—supporting a higher-value mix over time. Given consensus for a 23.07% year-over-year improvement in EBIT despite an expected loss, management commentary around utilization growth, sample flow, and additional payor traction for MRD will be a focal point for gauging operating leverage. The degree to which MRD pull-through increases broader next-generation sequencing and liquid biopsy volumes could amplify both revenue and gross margin in subsequent quarters. Near-term, the company’s disclosures on order counts, covered indications, and data publications will help anchor expectations for the cadence of MRD revenue ramp through 2026.

Watch Items That Could Move the Stock

Guidance updates will likely be the primary swing factor: investors will look for qualitative or quantitative confirmation that the full-year revenue range of 793.00–801.00 million US dollars remains intact, and for any color on quarterly phasing that frames the expected acceleration in the second half. Profitability commentary—especially around gross margin drivers, test-level economics, and the timing of EBIT improvement—will be parsed closely given last quarter’s -5.20% net margin and consensus for continued negative EBIT this quarter. Commercial execution markers such as order growth from health systems and oncologists, test menu expansion, and payor policy updates can influence the outlook for both revenue growth and cash conversion. Any incremental news on partnerships, real-world evidence supporting RaDaR ST, or expanded coverage decisions could shift sentiment positively by signaling a clearer path to higher-volume, higher-margin testing. Conversely, signals of slower adoption, tighter utilization management by payors, or unexpected cost inflation would weigh on perceptions of operating leverage this year. With several analysts leaning positive, confirmation of volume growth and margin resilience would validate the bullish case, while cautious guidance or slower MRD traction could bring expectations closer to the low end of full-year revenue indications.

Analyst Opinions

Bullish vs. bearish ratio: 3:0. The majority of recent institutional commentary is constructive, emphasizing new product catalysts and a path to above-consensus growth as 2026 progresses. Jefferies reiterated a Buy rating and lifted its price target to 15.00 US dollars, highlighting expectations that new products can drive above-consensus growth in 2026 and positioning the company favorably for revenue acceleration as adoption builds. TD Cowen maintained a Buy rating with a 14.00 US dollars target, citing a balanced setup into near-term prints and confidence that test menu expansion and commercial execution will sustain mid- to high-single-digit revenue growth in the near term. Needham reiterated its Buy rating with a 14.00 US dollars target, underscoring progress on strategic growth initiatives and a supportive reimbursement backdrop, while pointing to continued improvement in adjusted profitability as volume scales. The bullish camp’s key arguments coalesce around three pillars. First, execution: the prior quarter outperformance on revenue and adjusted EPS supports confidence that order flow and payor collections are trending well, with the current quarter’s 7.94% year-over-year revenue growth expectation seen as achievable. Second, mix: analysts expect higher-value assays and incremental MRD adoption to skew the revenue mix toward better unit economics, helping maintain or modestly expand gross margin from the 43.83% level observed last quarter. Third, operating leverage: despite an expected EBIT loss of -19.97 million US dollars, the 23.07% year-over-year improvement embedded in consensus is viewed as a sign that expense growth is decoupling from revenue growth, setting up for more visible progress toward profitability in the back half of 2026. Within that framework, the majority view anticipates that RaDaR ST will be a steadily compounding contributor rather than an immediate needle-mover, with the real value reflected in improved win rates in both clinical ordering and biopharma engagements. Analysts also note that the company’s full-year revenue guide of 793.00–801.00 million US dollars offers headroom for modest upside if adoption curves steepen and if reimbursement trends remain supportive. The group expects management on April 28, 2026 to reinforce confidence in volume growth, elaborate on MRD coverage and utilization, and provide clearer signposts on expense scaling, all of which would validate a path to sustained revenue growth with improving margin trajectory through 2026.